Mechanisms of unresponsiveness: T- and B-cell mediated mechanisms of anergy

Advances in Experimental Medicine and Biology

Volumn 489, Issue , 2001, Pages 109-117

  Greenwood, R ^a   Frelinger, J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN;

B LYMPHOCYTE; BLEEDING; BONE MARROW; CELL MATURATION; CLONAL ANERGY; CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE REARRANGEMENT; GENE THERAPY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMUS;

EID: 0035033747     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-1277-6_10     Document Type: Conference Paper

References (27)

1. Immunogenetic consequences of vascular anastamoses between bovine twins
2. Developmental stages in the human thymus
3. Negative selection of lymphocytes
4. Positive selection of lymphocytes
5. Reversal of in vitro T cell clonal anergy by IL-2 stimulation
6. B cell development: Signal transduction by antigen receptors and their surrogates
7. Naturally occuring antibodies against nine common antigens in human sera. I. Detection, isolation and characterization
8. Transgenic mice and analysis of B-cell tolerance
9. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals
10. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies
11. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors
12. Disappearance of a high response factor VIII inhibitor in a hemophiliac with AIDS
13. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the Multi-Center Hemophilia Cohort Study
14. Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC
15. Sustained expression of therapeutic levels of human factor VIII in mice
16. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy
17. Complete short-term correction of canine hemophilia A by in vivo gene therapy
18. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
19. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host
20. Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus
21. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors
22. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver
23. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
24. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
25. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
26. Humoral and cellular immunity to an encoded protein reduced by direct DNA rejection
27. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector